ISCO – Welcome to International Stem Cell Corporation

Kenneth C. Aldrich, Chairman, CEO and Co-Founder, has been active in venture capital investing and private equity since 1975. He is Co-founder and Chairman of International Stem Cell Corporation (ISCO), a Managing Director of Convergent Ventures, an early-stage life sciences investment company, and an active member of Tech Coast Angels. Through those entities and predecessor companies, he has provided early-stage funding and management for a variety of biomedical and technology start-ups, including WaveTec Vision Systems, an ophthalmic device company (as a Director and co-founder), Neurion Pharmaceuticals, Inc., a drug discovery and evaluation company (as a Director and co-founder), and Orfid Corporation, a developer of organic transistors (as a founder and financial advisor). He is also a director of Green Dot Corporation, the world’s largest issuer of prepaid debit cards. Mr. Aldrich holds degrees, with honors, from both Harvard University and Harvard Law School. E-Mail: kaldrich@intlstemcell.com.

Jeffrey Janus, President, has a proven track record extending over eighteen years of creating profitable commercial cell based businesses and building corporate value as a result. Jeffrey was a founder of Lifeline Cell Technology, the keystone company to ISCO’s portfolio of cellular companies. He led in the development and commercialization of Clonetics Corporation and the Clonetics brand of human cell products for both research and clinical use. Clonetics is the leading brand of human-cell based products, well known for quality and innovation. That company was successfully sold in 1995 after ten consecutive years of profitable growth exceeding 20%. Mr. Janus foresaw the need for human cells in therapy and created businesses in the contract manufacturing of human cells and culture media and human cells for clinical use. He has organized businesses providing unique research products using living cells to conduct drug screening in the pharmaceutical industry, product testing in the consumer products industry and basic research at Universities and Government laboratories. Critical staff from Clonetics Corporation agreed to join Lifeline largely based on the success of working Mr. Janus in the past. Mr. Janus has a MBA and a Bachelor's degree in Biochemistry.
E-Mail: JanusJ@lifelinecelltech.com.

William B. Adams, CPA, CFO and Co-Founder, has 30 years of experience in the corporate consulting
and financing arenas. Mr. Adams has provided seed capital and secondary and bridge financing to
numerous start-up companies both individually and as a manager of various private investment
partnerships. He is a Managing Member of Convergent Investors, LLC (also known as "CV-I"). Mr. Adams served as CFO of Neurion Pharmaceuticals, Inc., a CV-I portfolio company. Through investments prior to
the formation of Convergent Ventures, Mr. Adams is a co-founder of WaveTec Vision Systems, an
ophthalmic device company and Lifeline Cell Technology, LLC. He served as President of Wm. Adams Accountancy Corporation and was a founder of Dimensional Planning Group, a management consulting
and financial planning company. Previously, Mr. Adams was an accountant at Ernst & Ernst (now Ernst & Young). Mr. Adams holds a B.S. in Accounting from California State University, Long Beach and is on the alumni Board of Ernst & Young in Los Angeles.
E-mail: wadams@intlstemcell.com.

Andrei Semetchkine, Professor, Ph. D., Chief Business Officer, is a specialist in system analysis, strategic planning and corporate management, and the author of several scientific books. He is a member of the Russian Academy of Sciences. Professor Semetchkine was awarded the RF Government Award in Science and Technology in 2006. Since 2004 he has been the Deputy Director of the Institute of System Analysis of the Russian Academy of Sciences. Professor Semetchkine has over 20 years of experience in the creation and managing of holding business structures in different industry and scientific sectors. He is the Chairman of X-Master, Inc., a New Hampshire Corporation which holds real estate and other assets and investments.

Paul V. Maier, Director, has over 20 years of experience as a senior executive in biotechnology and pharmaceutical companies. Mr. Maier is currently an independent financial consultant.

Previously, Mr. Maier was Senior Vice President and Chief Financial officer of Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) a commercial stage biopharmaceutical company, a position he held from 1992 to 2007. From 1990 to 1992, Mr. Maier served as Vice President, Finance of DFS West, a division of DFS Group, LP a private multinational retailer. From 1984 to 1990, Mr. Maier was employed by ICN Pharmaceuticals, a pharmaceutical and biotechnology research products company, where he held various executive positions in finance and general management in ICN as well as SPI Pharmaceuticals, a publicly held subsidiary. Mr. Maier has served on the boards of public and private companies. Mr. Maier received an MBA from Harvard Business School and a BS from Pennsylvania State University.

Donald Wright, Director, brings to International Stem Cell Corporation over 30 years of experience in starting and nurturing emerging growth companies, both public and private. He is President and Founder of Everett, Washington-based Confluence Capital Group Inc., (www.confluencecap.com), which provides consulting services to institutional investors, debt holders and public and private companies.

Prior to Confluence Capital, Mr. Wright was President and CEO of Pacific Aerospace & Electronics, Inc., a company he founded in 1990, took public and ran until 2006. Under his leadership, Pacific Aerospace grew from annual sales of approximately $3 million in 1994 to over $112 million in 2000. Earlier, Mr. Wright was President and CEO of Washington-based Component Concepts, Inc., a company he founded in 1976. He is the recipient of numerous business and community awards, and was named one of the 50 fastest growing companies in Washington State for 1998, 1999 and 2000 by Deloitte & Touche. Additionally he was recognized by Deloitte & Touche as one of the 500 fastest growing companies in the United States for 1998, 1999 and 2000.

Mr. Wright served as an advisory board member for Central Washington University’s School of Business for six years and completed the UCLA Director Training and Certification Program.

Rouslan Semetchkine, Director, brings to International Stem Cell Corporation both scientific expertise and international relationships. He has for the past 5 years been pursuing an academic career and since May 2006 has been president of the New Hampshire corporation which invests in different types of assets. He is an honors graduate of the Moscow State University and is a specialist in the analysis of biological processes and mathematical modeling in biology. He is a Member of the American Mathematical Society.